Reviewing CloudMD Software & Services (OTCMKTS:DOCRF) and Schrodinger (NASDAQ:SDGR)

CloudMD Software & Services (OTCMKTS:DOCRF) and Schrodinger (NASDAQ:SDGR) are both healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

79.0% of Schrodinger shares are held by institutional investors. 10.1% of Schrodinger shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares CloudMD Software & Services and Schrodinger’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
CloudMD Software & Services	N/A	N/A	N/A
Schrodinger	-20.98%	-16.37%	-8.19%

Analyst Recommendations

This is a summary of current ratings and price targets for CloudMD Software & Services and Schrodinger, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CloudMD Software & Services	0	0	0	0	0.00
Schrodinger	1	3	3	0	2.29

Schrodinger has a consensus price target of $20.50, indicating a potential upside of 0.44%. Given Schrodinger’s stronger consensus rating and higher possible upside, analysts clearly believe Schrodinger is more favorable than CloudMD Software & Services.

Earnings & Valuation

This table compares CloudMD Software & Services and Schrodinger”s top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CloudMD Software & Services	N/A	N/A	N/A	N/A	N/A
Schrodinger	$255.87 million	5.89	-$103.26 million	($0.74)	-27.58

CloudMD Software & Services has higher earnings, but lower revenue than Schrodinger.

Summary

Schrodinger beats CloudMD Software & Services on 6 of the 9 factors compared between the two stocks.

About CloudMD Software & Services

CloudMD Software & Services Inc. offers healthcare services in Canada and the United States. It operates in two segments, Health and Productivity Solutions and Health and Wellness Services. The Health and Productivity Solutions segment provides health and productivity tools, including remote patient monitoring that allows clinics, health systems, benefit plans, and employers to track vital statistics of its patients, members, and employees; MyHealthAccess, a patient portal for online appointment booking and virtual care visits; health and wellness network solutions that focuses on enabling healthcare providers to be in constant connection with their patients and enables patients to be cared for digitally, remotely, and holistically; real time intervention platform that enables an automated real time inquiry of disparate data sources across multiple domains, and identifies indicators and compute risk scores; and medical reference library, a health educational platform that provides peer-reviewed resources for healthcare professionals. The Health and Wellness Services segment offers organizations with an employee and family assistance program; mental health care, such as coaching, therapy, and treatment for chronic conditions; health coaching; medical assessments; and occupational health and absence management services through the company's integrated connected platform Kii. This segment also provides virtual care and rehabilitation and assessments. The company was formerly known as Premier Health Group Inc. and changed its name to CloudMD Software & Services Inc. in February 2020. CloudMD Software & Services Inc. was incorporated in 2013 and is headquartered in Vancouver, Canada.

About Schrodinger

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.